VECTICAL (calcitriol) by Galderma is clinical pharmacology man's natural supply of vitamin d depends mainly on exposure to the ultraviolet rays of the sun for conversion of 7-dehydrocholesterol in the skin to vitamin d 3 (cholecalciferol). First approved in 2009.
Drug data last refreshed Yesterday
VECTICAL is a topical calcitriol (active vitamin D3) ointment indicated for psoriasis and various metabolic bone diseases including secondary hyperparathyroidism and renal osteodystrophy. It works by binding to vitamin D receptors in the intestine and bone to regulate calcium and phosphorus metabolism, mimicking the body's natural active vitamin D hormone. The drug is particularly valuable for patients with chronic kidney disease who cannot adequately synthesize calcitriol endogenously.
VECTICAL operates in a niche therapeutic area with minimal Part D spend ($2M) and declining patent protection, signaling a small, mature brand team focused on maintenance rather than growth initiatives.
CLINICAL PHARMACOLOGY Man's natural supply of vitamin D depends mainly on exposure to the ultraviolet rays of the sun for conversion of 7-dehydrocholesterol in the skin to vitamin D 3 (cholecalciferol). Vitamin D 3 must be metabolically activated in the liver and the kidney before it is fully…
Worked on VECTICAL at Galderma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Vitamin D3 Analog
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Eldecalcitol and Calcitriol in Postmenopausal Women With Low Bone Mineral Density or Mild Osteoporosis
Oral Calcitriol With Ketoconazole in CRPC
Long Term Safety and Efficacy Study of Calcitriol 3 mcg/g Ointment in Pediatric Subjects With Plaque Psoriasis
PK and PD Study of Calcitriol 3 mcg/g Ointment in Pediatric Subjects With Plaque Psoriasis
A Pilot Clinical Study Evaluating the Effect of Parathyroid Hormone (PTH) Lowering On Erythropoietin Consumption in Calcitriol-Resistant Patients
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moVECTICAL shows zero linked job postings, reflecting its niche market position and mature lifecycle stage; career opportunities are primarily maintenance-focused roles in smaller dermatology or nephrology brand teams rather than growth-oriented positions. Professionals seeking dynamic launch experience or high-commercial-velocity environments should consider the competitive GLP-1 or SGLT2 inhibitor franchises instead.